FDA: New Warning for Procrit, Epogen, Aranesp

New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease puts them at risk of heart attacks, stroke, and death. More conservative dosing is needed.

Click here to read the full story.

Post a Comment

No comments yet!
Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.